Compare GEO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | CNTA |
|---|---|---|
| Founded | 1984 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 6.1B |
| IPO Year | 1996 | 2021 |
| Metric | GEO | CNTA |
|---|---|---|
| Price | $22.82 | $39.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $39.67 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 29.13 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $2,263,420,000.00 | $15,000,000.00 |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $79.76 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $10.95 |
| 52 Week High | $27.90 | $40.26 |
| Indicator | GEO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 70.14 |
| Support Level | $16.06 | $39.36 |
| Resistance Level | $23.18 | $39.86 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.10 | -0.19 |
| Stochastic Oscillator | 65.08 | 67.19 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.